Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paromomycin Sulfate

FDA-approved product (capsule, oral), marketed as Humatin, Paromomycin Sulfate.

Registered studies
36
Lab records
3
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paromomycin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amebiasis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC A07AA06

Repurposing investigation

Paromomycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA71.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae96.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 2 of 2 lab records
Open Paromomycin Sulfate in ChEMBL Registered studies below
Show the 3 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paromomycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

    NCT00703924 · start 2003-03

    Registered record
    Registry ID
    NCT00703924
    Conditions
    Cutaneous Leishmaniasis
    Interventions
    WR 279,396; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-03
    Completion
    2005-11
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis
    InterventionWR 279,396; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients

    NCT00057486 · start 1997-09

    Registered record
    Registry ID
    NCT00057486
    Conditions
    HIV Infections; Cryptosporidiosis
    Interventions
    IL-12
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    1997-09
    Completion
    2005-06
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Cryptosporidiosis
    InterventionIL-12
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis

    NCT00004444 · start 1994-11

    Registered record
    Registry ID
    NCT00004444
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    paromomycin; streptomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1994-11
    Completion
    2001-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    Interventionparomomycin; streptomycin
    PhaseNot applicable
    Registry statusCompleted

  • A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3

    NCT00000771

    Registered record
    Registry ID
    NCT00000771
    Conditions
    Cryptosporidiosis; HIV Infections
    Interventions
    Paromomycin sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1996-09
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptosporidiosis; HIV Infections
    InterventionParomomycin sulfate
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Chronic Cryptosporidiosis in AIDS Patients

    NCT00001128

    Registered record
    Registry ID
    NCT00001128
    Conditions
    Cryptosporidiosis; HIV Infections
    Interventions
    Interleukin-12; Paromomycin sulfate; Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    2005-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptosporidiosis; HIV Infections
    InterventionInterleukin-12; Paromomycin sulfate; Azithromycin
    PhaseNot applicable
    Registry statusTerminated

  • Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

    NCT01641796

    Registered record
    Registry ID
    NCT01641796
    Conditions
    Leishmaniasis, Cutaneous
    Interventions
    Paromomycin
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis, Cutaneous
    InterventionParomomycin
    PhaseNot recorded
    Registry statusNo longer available